to HDEC NZ, SOP for DSMB member independence NZ, SOP for safety oversight governance NZ, SOP for inspection readiness DSMB NZ, SOP for ethics committee DSMB NZ, SOP for DSMB communications NZ, SOP for trial subject safety DSMB NZ, SOP for DSMB archiving NZ”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Published on 21/12/2025

Data Safety Monitoring Board (DSMB) Oversight and Reporting SOP

Department	Clinical Research
SOP No.	CS/NZ-DSMB/204/2025
Supersedes	N.A.
Page No.	1 of 26
Issue Date	28/08/2025
Effective Date	05/09/2025
Review Date	05/09/2027

Purpose

The purpose of this SOP is to outline the establishment, responsibilities, and operational procedures for the Data Safety Monitoring Board (DSMB) in clinical trials conducted in New Zealand. It ensures compliance with Medsafe, HDEC, and international GCP requirements, protecting trial participants through independent oversight of safety and efficacy data.

Scope

This SOP applies to all clinical trials in New Zealand requiring independent DSMB oversight due to high-risk interventions, large sample sizes, or regulatory/ethics committee requirements. It covers DSMB charters, meeting schedules, safety data review, interim reporting, and archiving of DSMB documentation.

Responsibilities

• Sponsor: Establishes DSMB, provides charter, and ensures access to safety data.
• Principal Investigator (PI): Provides timely safety reports to DSMB and complies with recommendations.
• DSMB Members: Independently review safety/efficacy data, make recommendations regarding trial continuation, modification, or termination.
• Regulatory Affairs (RA): Submits DSMB reports to HDEC and Medsafe when required.
• Quality Assurance (QA): Audits DSMB operations and documentation.

Accountability

The sponsor’s Head of Clinical Operations is accountable for ensuring DSMB oversight processes are in place. DSMB Chair is accountable for impartial recommendations regarding trial safety and continuation.

Procedure

1. DSMB Establishment

1. Identify qualified independent experts in medicine, statistics, and ethics.
2. Draft and approve DSMB Charter (Annexure-1).
3. Document member independence declarations.

2. Safety Data Review

1. Collect safety data from investigators and sponsor databases.
2. Provide interim analyses to DSMB for blinded/unblinded review.

3. DSMB Meetings

1. Schedule periodic meetings (quarterly or as required by trial risk).
2. Document minutes and recommendations in DSMB Meeting Log (Annexure-2).

4. Recommendations and Communication

1. DSMB issues recommendations to sponsor regarding trial continuation, modification, or termination.
2. Sponsor communicates DSMB recommendations to PI, CRO, HDEC, and Medsafe.

5. Archiving

1. Maintain DSMB records in TMF and ISF.
2. Archive all reports for a minimum of 10 years post-trial completion.

Abbreviations

• DSMB: Data Safety Monitoring Board
• PI: Principal Investigator
• RA: Regulatory Affairs
• QA: Quality Assurance
• CRO: Contract Research Organization
• HDEC: Health and Disability Ethics Committees
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. DSMB Charter (Annexure-1)
2. DSMB Meeting Log (Annexure-2)
3. DSMB Recommendations Log (Annexure-3)

References

• Medsafe — Medicines and Medical Devices Safety Authority
• HDEC — Health and Disability Ethics Committees
• ICH E6(R2) Good Clinical Practice
• WHO Clinical Trial Oversight Guidelines

Version: 1.0

Approval

Prepared By	Checked By	Approved By
Name: Rajesh Kumar Date: 20/08/2025 Signature: __________	Name: Sunita Reddy Date: 22/08/2025 Signature: __________	Name: Dr. Meera Iyer Date: 28/08/2025 Signature: __________

Annexures

Annexure-1: DSMB Charter

Document	Date	Prepared By	Status
DSMB Charter	01/08/2025	RA Team	Approved

Annexure-2: DSMB Meeting Log

Date	Meeting No.	Summary	Chair
15/08/2025	1	Reviewed interim safety report	Prof. John Matthews

Annexure-3: DSMB Recommendations Log

Date	Recommendation	Action Taken	Approved By
16/08/2025	Continue without modification	Implemented	Sponsor

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
28/08/2025	1.0	Initial SOP for DSMB oversight and reporting in New Zealand trials.	New SOP created for Medsafe, HDEC, and GCP compliance.	Head of Clinical Research

For more SOPs visit: Pharma SOP.